Bridgehead International, a biopharmaceutical consultancy group, and RXB Management Consulting of Shanghai, China, have entered into an agreement to jointly provide services to clients in the pharmaceutical, medical device and diagnostics sectors.
Bridgehead and RXB have established a team so as to support their Chinese clients in terms of regulatory strategy and SFDA registration services, pricing policy analysis and interpretation, Pharmiweb.com reported.
The tie up also aims to provide services regarding the competitor pricing analysis, pricing strategy for new products etc.
RXB partner and managing director Betty Su was quoted by Pharmiweb.com as saying that the RXB was set up to facilitate Sino-Foreign business transaction and knowledge transfer in the health care sector.
“I’m convinced that the collaboration between the two companies – RXB and Bridgehead – will benefit our common clients in terms of developing a solid understanding of the exciting and yet complex Chinese health care market,” Su said.
RXB specialises in pharmaceutical and medical device market analysis, market entry and partnering strategy and solutions for the Chinese market.